Source: Fox News
Summary
A new experimental medication, DFNZ, has shown strong pain relief in early studies without the risks associated with typical opioids. The medication, developed by the National Institute on Drug Abuse (NIDA), is a derivative of nitazene, a class of synthetic opioid compounds. DFNZ provided at least two hours of pain relief in mice after just five or 10 minutes in the brain, without the serious risks associated with standard opioids, such as addiction potential and depressed breathing. The study’s findings were published in the journal Nature.
Our Reading
The advice sounds familiar. A new medication promises to provide strong pain relief without the risks associated with opioids. The study’s findings are promising, but experts caution that more research is needed to fully understand the drug’s addictive potential and long-term effects. The medication’s ability to increase oxygen flow to the brain rather than decrease it is a notable benefit. However, the narrow therapeutic threshold of this class of drugs raises concerns about the risk of addiction. As with any new medication, more research is needed to determine its safety and efficacy in humans.
Author: Evan Null
